Stockreport

Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Ventus Therapeutics licenced NNC6022-0001 to Novo Nordisk in September 2022. The study aims to thoroughly evaluate the pharmacokinetics, pharmacodynamics, and safety [Read more]